SCHEMBL9910980

SCHEMBL9910980

CN1CC[C@@H]2c3ccccc3O[C@@H]2C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 3/20 0.48
OPRM1 P35372 2/20 0.44
CHRM2 P08172 1/20 0.41
HTR1A P08908 1/20 0.41
ADRA2A P08913 1/20 0.41
DRD2 P14416 1/20 0.41
GABRA1 P14867 1/20 0.41
ADRA2B P18089 1/20 0.41
ADRA2C P18825 1/20 0.41
DRD1 P21728 1/20 0.41
DRD4 P21917 1/20 0.41
SLC6A2 P23975 1/20 0.41
ADRA1D P25100 1/20 0.41
HTR2A P28223 1/20 0.41
HTR2C P28335 1/20 0.41
SLC6A4 P31645 1/20 0.41
ADRA1A P35348 1/20 0.41
HRH1 P35367 1/20 0.41
ADRA1B P35368 1/20 0.41
DRD3 P35462 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12835652 1.00 SIGMAR1 (0.48) SIGMAR1OPRM1CHRM2HTR1AADRA2A
SCHEMBL9963160 0.80 OPRM1 (0.39) OPRM1CHRM2CHRNB4CHRNA3CHRNB2
SCHEMBL171335 0.80 CHRNB4 (0.47) SIGMAR1CHRM2DRD2DRD4CHRNB4
SCHEMBL11364232 0.79 CHRM2 (0.60) SIGMAR1CHRM2HTR1AADRA2ADRD2
SCHEMBL2225619 0.78 F11 (0.46) OPRM1CHRM2
SCHEMBL16551115 0.77 HTR6 (0.60) CHRM2SLC6A2HTR2AHTR2CHTR2B
SCHEMBL11555846 0.76 SIGMAR1 (0.43) SIGMAR1SLC6A2SLC6A4HRH1HTR6
SCHEMBL12835650 0.76 SIGMAR1 (0.40) SIGMAR1CHRM2HTR1AADRA2AADRA2B
SCHEMBL11556920 0.76 SIGMAR1 (0.43) SIGMAR1SLC6A2SLC6A4HRH1HTR6
SCHEMBL13836477 0.76 F11 (0.46) OPRM1CHRM2DRD2DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180099972-A1 Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same UNIV DREXEL (US) 2018-04-12 US disclosed
US-9856260-B2 Compounds useful for inhibiting metastasis from cancer and methods using same DREXEL UNIVERSITY (US) 2018-01-02 US disclosed
US-20160264587-A1 Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same UNIV DREXEL (US) 2016-09-15 US disclosed
US-9375474-B2 Compounds useful for inhibiting metastasis from cancer and methods using same DREXEL UNIVERSITY (US) 2016-06-28 US disclosed
US-20130156761-A1 Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same Alliance Discovery, Inc. (US) 2013-06-20 US disclosed
US-8435993-B2 Methods of inhibiting metastasis from cancer PHILADELPHIA HEALTH AND EDUCATION CORPORATION (US) 2013-05-07 US disclosed
US-20120141471-A1 Methods of Inhibiting Metastasis from Cancer Alliance Discovery, Inc. 2012-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180099972-A1 Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same CX3CR1, CCL2, CCR5 SIGMAR1 1873/4885OPRM1 703/4885CHRM2 273/4885
US-20120141471-A1 Methods of Inhibiting Metastasis from Cancer CX3CR1, CXCR3, CCR5 SIGMAR1 1885/4885OPRM1 591/4885CHRM2 214/4885
US-20130156761-A1 Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same CX3CR1, CCL2, CCR5 SIGMAR1 1873/4885OPRM1 703/4885CHRM2 273/4885
US-20160264587-A1 Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same CX3CR1, CCL2, CCR5 SIGMAR1 1873/4885OPRM1 703/4885CHRM2 273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.